Delivery Order SPE2DB20D3303-SPE2DB25FA1YR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,859.94 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in a 120 mL container. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) with a ceiling value of $1,731.16. This competitively awarded, non-set-aside contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $2,625.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 120 mL quantities, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 28, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a transaction under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,957.94 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price delivery order was issued on a non-set-aside basis and represents a pediatric ADHD medication supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA1YRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, to supply Quillivant XR 25 mg/5 ml suspension in a 150ml quantity. This firm fixed-price delivery order, valued at $1,577.04, was competitively awarded without a set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. Quillivant XR is an extended-release liquid formulation of methylphenidate used to treat attention-deficit/hyperactivity disorder and represents part of the company's broader pharmaceutical supply portfolio for federal military and veteran healthcare systems. As a child contract action under the DLA Troop Support Medical SPE2DX prime vendor agreement, this delivery order exemplifies AmerisourceBergen's role as a critical distributor of specialty pharmaceuticals and medical supplies to the Defense Health Agency and other federal healthcare programs. The company maintains an extensive track record of fulfilling federal medical procurement requirements across diverse therapeutic domains, ranging from neurological treatments to diabetes medications and pain management pharmaceuticals. This delivery order reflects the company's continued participation in the DLA's pharmaceutical supply chain supporting military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 7/30/25 |